TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06429150: VELA-2: Phase 3 Study of Sonelokimab IL-17A/IL-17F Nanobody in Moderate-to-Severe Hidradenitis Suppurativa

Sponsor: MoonLake Immunotherapeutics AG · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 400 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$3,773,508

Rescue Site Savings

+$2,491,248

Unlock Full NCT06429150 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06429150 Rescue Dossier →